Related Experiment Video

Updated: Jul 5, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.6K

Inflammation as a New Therapeutic Target among Older Patients with Ischemic Heart Disease

Daniela Maidana1, Andrea Arroyo-Álvarez1, Andrea Arenas-Loriente2

  • 1INCLIVA-Instituto de Investigación Sanitaria, Biomedical Research Institute, 46010 Valencia, Spain.

Journal of Clinical Medicine
|January 23, 2024
PubMed

Insights

Older patients with ischemic heart disease (IHD) face higher risks of recurrent events. Targeted anti-inflammatory therapies may improve outcomes and quality of life for this vulnerable population.

Area of Science:

  • Cardiology
  • Gerontology
  • Immunology

Background:

  • Cardiovascular diseases, particularly ischemic heart disease (IHD), represent a significant global health burden.
  • Older adults with IHD are prone to recurrent ischemic events despite standard treatments, worsening prognosis.
  • Inflammation is a key factor in aging and atherosclerosis development, suggesting a therapeutic target.

Purpose of the Study:

  • To review the role of inflammation in older patients with IHD.
  • To explore the potential of anti-inflammatory interventions in this demographic.
  • To assess the impact of these therapies on clinical outcomes and quality of life.

Main Methods:

  • Literature review of studies on inflammation, aging, atherosclerosis, and IHD.
  • Analysis of emerging anti-inflammatory therapies and their efficacy in high-risk populations.
  • Synthesis of evidence regarding clinical outcomes and quality of life improvements.

Main Results:

  • Inflammation is closely associated with the aging process and atherosclerosis progression.
  • Anti-inflammatory therapies have demonstrated potential in mitigating ischemic events in at-risk groups.
  • Targeted interventions may offer benefits beyond current pharmacological approaches.

Conclusions:

  • Targeted anti-inflammatory strategies hold promise for managing IHD in older adults.
  • These interventions could enhance clinical outcomes and improve the quality of life for elderly IHD patients.
  • Further research into specific anti-inflammatory agents is warranted for this population.

Keywords:
cardiovascular diseaseinflammationischemic heart diseaseolder patients

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.2K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

396

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Inflammation01:38

Inflammation

Overview
53.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591